Otsuka (OTSKY) to Announce Quarterly Earnings on Thursday

Otsuka (OTCMKTS:OTSKY) will likely be issuing its resultson Thursday, July 30th. Analysts expect Otsuka to announce earnings of $0.5060 per share and revenue of $3.9475 billion for the quarter.

Otsuka (OTCMKTS:OTSKY) last issued its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. On average, analysts expect Otsuka to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Otsuka Stock Up 0.8%

Shares of OTSKY opened at $34.30 on Tuesday. Otsuka has a 52-week low of $23.31 and a 52-week high of $37.52. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $34.23 and a two-hundred day simple moving average of $33.38. The company has a market capitalization of $36.84 billion and a PE ratio of 14.47.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.